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pathogenesis of non-alcoholic fatty liver disease 
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Abstract
Nonalcoholic fatty liver disease is increasingly regarded as a hepatic manifestation of metabolic syndrome, and the 
severity of nonalcoholic fatty liver disease seems to increase in parallel with other features of metabolic syndrome. 
Excess lipid accumulation in the liver cells is not only a mediator of Metabolic Syndrome and indicator of a lipid 
overload but also accompanied by a range of histological alterations varying from 'simple' steatosis to nonalcoholic 
steatohepatitis, with time progressing to manifest cirrhosis. Hepatocellular carcinoma may also occur in nonalcoholic 
steatohepatitis -related cirrhosis with a mortality rate similar to or worse than for cirrhosis associated with hepatitis C. 
This review summarizes the knowledge about the causal relationship between hepatic fat accumulation, insulin 
resistance, liver damage and the etiological role of hepatic fat accumulation in pathogenesis of extra- and intra-hepatic 
manifestations. Special emphasis is given suggestions of new targets treatment and prevention of nonalcoholic fatty 
liver disease.
Introduction
Nonalcoholic fatty liver disease (NAFLD), no more than 
15 years ago considered as rare, has now reached epi-
demic propertions in China and has a major clinical and 
research priority [1]. It is only since a decade or so that 
nonalcoholic fatty liver disease is considered to be a man-
ifestations of insulin resistance[2,3]. The fact that insulin 
resistance and compensatory hyperinsulinaemia have 
central etiologic roles in the development of both meta-
bolic syndrome and NAFLD makes the excessive accu-
mulation of triglycerides (TG) in the liver especially 
interesing [4]. The severity of NAFLD increases in paral-
lel with other features of the metabolic syndrome, sup-
porting that NAFLD is its hepatic manifestation [5].
Although current therapy presently is limited to sugges-
tions of lifestyle changes and control of associated meta-
bolic disorders, experimental studies and clinical 
observations do suggest also other modalities of treat-
ment. As an example, a proof-of-concept study suggest 
that administration of pioglitazone improvements in both 
metabolic and histological manifestations of disease in 
subjects with nonalcoholic steatohepatitis[6].
NAFLD has the potential to progress through the inflam-
matory phase of nonalcoholic steatohepatitis (NASH) to 
fibrosis, cirrhosis (20%), and in some cases (9%) to liver 
failure or hepatocellular carcinoma (HCC) (1%) [7,8]. The 
reasons why some patients develop advanced disease 
while others have non- och less progressive liver disease 
are not fully understood. The mechanism of liver injury 
in NAFLD/NASH is suggested to be a 'two hit phenome-
non' where the 'first hit' consists in inflammation and 
development of steatosis, which sensitizes the liver to a 
variety of 'second hits' lead to fibrosis [7,9]. It is also 
increasingly recognized that fat-induced insulin resis-
tance in the liver causes activation of proinflammatory 
pathways, which will lead to modification of this 'two hit' 
process.
Identifying patients at risk for transition from hepatic ste-
atosis to NASH and fibrosis with noninvasive techniques 
are the great challenges in hepatology [9]. Therefore, 
combining of the hepatologist's knowledge of human 
hepatic pathology and pathophysiology with the endocri-
nologist's knowledge of insulin signaling and the regula-
tion of glucose and lipid metabolism in the liver will help 
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to better understand the process, and hopefully also, help 
to find new targets for the treatment and prevention of 
NAFLD.
The causal relationship between hepatic fat accumulation 
and insulin resistance
Hepatocellular steatosis is the hallmark of NAFLD. The 
histological criterion for the diagnosis of NAFLD is the 
presence of fat in more than 5% of the hepatocytes. The 
accumulation of fat usually starts in zone 3 and will in 
more severe cases may occupy whole acinus[10-12]. The 
lipid droplets in liver consist mainly in triglycerides. The 
contribution of different non-esterified fatty acids 
(NEFA) sources to hepatic triglycerides parallel to the 
VLDL triglycerides, includes: circulating NEFA pool con-
tributed 81% of hepatic and VLDL triglycerides in fasting 
conditions and 61% postprandially, dietary NEFA pool 
contributed 10% in fasting conditions and 26% postpran-
dially, whereas de novo fatty acid(DNL) contributed 7% in 
fasting and 9% postprandially[13](Fig 1).
Insulin resistance is defined as an inadequate response to 
the physiologic effects of circulating insulin in specific 
target tissues, such as skeletal muscle, liver, and adipose 
tissue,. The subjects with impaired glucose tolerance 
(IGT) demonstrate a marked muscle insulin resistance 
but only mild hepatic insulin resistance. Subjects with 
impaired fasting glucose (IFG), however, demonstrate 
severe hepatic insulin resistance but normal or near-nor-
mal muscle insulin sensitivity[14]. Epidemiological stud-
ies demonstrate that the two categories constitute two 
distinct populations, which only partially overlap, sug-
gesting that IGT and IFG represent two distinctly differ-
ent metabolic abnormalities [15]. However, it must be 
regarded as undisputable, that a strong association exists 
between insulin resistance and excess lipid accumulation 
in nonadipose tissues, particularly muscle and liver.
Although an association between NAFLD and insulin 
resistance is well accepted, it remains unclear whether 
insulin resistance causes the excessive accumulation of 
TG in liver, or it is the increase in TG itself or of its 
metabolite intermediates that plays the most causal role 
in the development of hepatic or systemic insulin resist-
ence [16]. Some investigators postulate that liver fat accu-
mulation is a result, rather than cause, of peripheral 
insulin resistance in obesity. In skeletal muscle, periph-
eral IR will primarily affect a large portion of the total 
glucose uptake (>80-90%), while in adipose tissue, insulin 
resistance will induce an impaired anti-lipolytic action of 
insulin and increased release of NEFA [17,18]. Elevated 
plasma concentrations of glucose and fatty acids may pro-
mote hepatic fatty acid and triglyceride uptake and syn-
thesis and impair β-oxidation [19]. As a result, an 
accumulation of triglycerides in the liver will occurs, 
leading to hepatic steatosis. The proposed mechanism for 
insulin resistance leading to diabetes is thus: IR in skeletal 
muscle T peripheral and portal vein hyperinsulinemia T 
hepatic steatosis T hepatic IR T DM2.
However, several observations indicate that steatosis can 
be caused also by intra-hepatic alterations in glucose and 
fat metabolism, which are independent of extrahepatic 
conditions[20,21]. Three consecutive days of feeding a 
high fat diet is known, also in the absence of significant 
peripheral fat accumulation to cause hepatic fat accumu-
lation and hepatic insulin resistance and this prior to the 
development of peripheral insulin resistence[22]. This 
study demonstrated that short term fat feeding will cause 
a 3-fold increase in liver and fatty acyl-CoA content, but 
not alter fasting plasma glucose concentration and the 
basal rate of endogenous glucose production (EGP), indi-
cating that hepatic fat accumulation from dietary NEFA 
pool is not necessarily associated with insulin resis-
tance[23].
Decreased insulin clearance has also been suggested as 
another pathway for hyperinsulinemia in liver. Insulin 
clearance is decreased in advanced liver disease, which is 
regarded as one of the main causes of hyperinsulinemia 
in iver cirrhosis [24]. The first organ to be impacted fol-
lowing insulin secretion is the liver, where a substantial 
proportion of secreted insulin is cleared via receptor 
mediated process [25,26], estimated in dogs to be app 
50% [27,28] and in humans 40-80% [25,29-32]. Both 
hepatic insulin sensitivity and whole body insulin clear-
ance were in this study measured directly by the euglyce-
mic hyperinsulinemic insulin clamp technique and liver 
fat measured by proton magnetic resonance spectroscopy 
in a group of nondiabetic subjects. The content of liver fat 
correlated significantly with impaired clearance of insulin 
(r = 0.43, P < 0.0001) and with hepatic insulin sensitivity 
(r = -0.40, P = 0.0002) [33,34]. The extent to which 
hepatic fat accumulation and impaired insulin clearance 
contribute to hyperinsulinemia can not yet be regarded as 
fully understood.
As discussed above (Fig 2), the peripheral insulin resis-
tance could well contribute to a causal role for hepatic 
steatosis, but NAFLD and hepatic insulin resistance is 
also regarded as a primary cause of of T2 MD.
The symptoms of NAFLD vary considerably from person 
to person, as some individuals may have few or no notice-
able symptoms until they are incidentally diagnosed by 
elevated levels of aminotransferase and by ultrasound. 
Other individuals will present with extremely high levels 
of hyperglycemia and classical symptoms of diabetes such 
as thirst, frequent urination, and weight loss.
The accumulation of triglycerides in liver is not equal to 
increased liver damage
Minimal histopathology criteria are used for diagnosis of 
NAFLD. Assessment of steatosis with reproducible semi-Liu et al. Lipids in Health and Disease 2010, 9:42
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quantitative methods use a three-stage scale to evaluate 
the percentage of liver parenchyma occupied by steatotic 
hepatocytes: I. 0-33% (or 0-5%, 5-33%), II 33-66%and III 
more than 66%[12]. Although hepatic steatosis is a key 
component of steatohepatitis, it is not known if patients 
with greater amounts of steatosis are more likely to 
develop steatohepatitis than those with mild steatosis. 
The histological definition of steatohepatitis does not 
require a particular amount of steatosis, and, steatosis 
will often decrease and may even be completely absent in 
cases with advanced fibrosis and cirrhosis [11,35].
Several findings suggest that hepatic triglycerides per se 
are not toxic and may, in fact, even protect the liver from 
lipotoxicity by buffering the accumulation of fatty 
acid[36,37]. Yamaguchi et al [38] demonstrated that inhi-
bition of TG synthesis (mediated through the reduction 
in DGAT2 activity) will improve liver steatosis, but at a 
price of increased liver damage. Levels of hepatic fatty 
acids, cytochrome P450, and markers of lipid peroxida-
tion and oxidant stress, as well as fibrosis, were in this 
study all markedly increased, Recent findings confirm 
that the ability to synthesize triglycerides may, in fact, be 
protective in obesity. When hepatocyte triglyceride syn-
thesis is inhibited, free fatty acids will accumulate in the 
liver, and swtimulate oxidizing systems that increase 
hepatic oxidative stress and liver damage[39,40]. Further-
Figure 1 Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease (Kerry L. Don-
nelly, et al, J. Clin. Invest. 2005;115:1343-1351).Liu et al. Lipids in Health and Disease 2010, 9:42
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more, feeding an n-3 PUFA-enriched diet failed to pre-
vent lipotoxic hepatocellular injury and inflammatory 
recruitment, although activated PPAR alpha and sup-
pressed hepatic de novo lipogenesis[39].
The differential toxicity of various FAs is relate directly to 
its ability to promote triglyceride accumulation[39]. The 
exogenous or endogenous generated unsaturated FAs will 
reduce palmitate-induced apoptosis by promoting palmi-
tate incorporation into triglycerides. Moreover, oleic acid, 
as well as palmitic acid, is toxic to cells with impaired 
capacity to synthesize triglycerides. Exposure of human 
hepatocytes to monounsaturated fatty acids (MUFAs) 
results in lipid accumulation without any changes in cell 
viability. In contrast, cells incubated with saturated fatty 
acids (SFAs) decrease significantly their viability in addi-
tion yo increasing their caspase activation and degree of 
apoptosis, parallel to only minor lipid droplet accumula-
tion[39].
Stearoyl-CoA desaturase-1 (SCD-1), the enzyme that 
converts SFA to MUFA, appears to provide an important 
metabolic control mechanism in the biochemistry and 
physiology of lipid metabolism. Genetic or pharmacolog-
ical inhibition of SCD1, sensitizes hepatic cells to SFA-
induced apoptosis. SCD1-/- mice on the MCD diet dem-
onstrate decreased steatosis and markedly increased 
hepatocellular apoptosis, liver injury, and fibrosis com-
pared to SCD1+/+ mice, whereas feeding MUFA pre-
vents the MCD-induced injury[41].
The studies referred to above clearly show that increased 
serum free fatty acid, rather than the excess lipid accumu-
lation in liver cells serves as a parameter of degree of liver 
damage, and might be considered as a future target for 
preventing and therapy of steatohepatitis in patients with 
NAFLD. Findings that inhibition of the expression of 
SCD-1 might also be beneficial in the treatment of obe-
sity, diabetes, and other metabolic diseases [42-45].
However, it is still quite possible that under the condi-
tions of enhanced TG synthesis, the capacity will be 
insufficient to buffer detoxifying of excess fatty acids. 
Liver damage could then occur as a result of fatty acid-
induced lipotoxicity and/or of a combination of both 
lipotoxicity and severe steatosis. A recent study shows 
that the severity of steatosis in NAFLD on histopathology 
is positively associated with lobular inflammation, zone 3 
fibrosis and definite steatohepatitis, suggesting that 
NAFLD patients with severe steatosis (affecting >66% of 
liver parenchyma) are most likely to have NASH [46]. We 
currently mainly relying on liver biopsies to confirm the 
diagnosis and indicate prognosis, as this far hepatic ultra-
sound and serum transaminases are of limited value in 
estimation of hepatic inflammation and fibrosis, How-
ever, ultrasonography is still by far the most common 
method of diagnosing NAFLD in clinical practice, espe-
cially as it has a very good sensitivity and specificity in 
detecting severe steatosis(>33% fat on liver biopsy), 
although the sensitivity of ultrasonography is not satisfac-
tory, particularly when hepatic fat infiltration is above 
33% [47,48]. The positive relationship between the sever-
ity of steatosis and other elements of NASH (i.e. inflam-
mation, ballooning, and fibrosis) provides noninvasive 
techniques to identify patients at risk for transition from 
hepatic steatosis to NASH and fibrosis. However, we are 
still unable to determine if patients with severe steatosis 
do faster progress to full blown steatohepatitis than those 
with milder forms of steatosis.
Fat-induced activation of chronic SIRS and NASH in the 
progression of NAFLD
NAFLD is a liver disease with a wide histological spec-
trum ranging from 'simple' steatosis with a generally 
benign course to nonalcoholic steatohepatitis (NASH), 
which usually is a more progressive form of the disease 
[11]. Progressive fibrosis occurs in 10-15% of patients 
with NASH and cirrhosis may develop in 15-25% of the 
cases [49,50]. Once developed, 30% to 40% of these 
patients succumb a liver-related death over a 10-year 
period [51,52], a mortality rate similar to[53,54] or worse 
than cirrhosis associated with hepatitis C. NASH-associ-
ated cirrhosis can also develop into into a subacute liver 
failure, or progress to hepatocellular cancer [55], as well 
as reoccur after liver transplantation.
Figure 2 Diagram of potential sources of and mechanisms for the 
accumulation of fat in the liver. Excess caloric intake plays a central 
role for inducing obesity and thus contributing to insulin resistance. 
Obesity may additionally impact fat accumulation in the liver by de-
creasing adiponectin levels and insulin resistance contributes to NA-
FLD directly by increasing de novo lipogenesis and indirectly by 
increasing FFA flux to the liver via decreased inhibition of lipolysis. In 
addition, excess dietary fat intake directly could also contribute to a 
causal role in hepatic steatosis(modified from Kristina M. The Journal 
of Clinical Endocrinology & Metabolism 2006; 91: 4753-4761).
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The reasons why some patients develop advanced dis-
ease, while others have indolent liver disease, are not fully 
understood. The mechanism of liver injury in NAFLD/
NASH is thought to follow, as mentioned above, a 'two hit 
pathway during which the steatosis sensitizes the liver to 
a variety of second hits, which lead to fibrosis and inflam-
mation[7]. The 'first hit', hepatic triglyceride accumula-
tion, or steatosis, increases the susceptibility of the liver 
to injury- mediated 'second hits'-changes, such as inflam-
matory cytokines/adipokines, mitochondrial dysfunc-
tion and oxidative stress, which in turn promote the 
development to steatohepatitis and/or fibrosis [9,56]. 
There is an increasing recognition of the fact that fat-
induced insulin resistance causes activation of proinflam-
matory pathways in the liver, which with time might lead 
to modification of the theory.
Most studies on the role of hepatic innate immunity in 
NAFLD has been generated by studying leptin-deficient 
(ob/ob) mice and leptin-resistant (fa/fa) rats, animals, 
which spontaneously develop fatty livers and naturally 
exhibit features, such as insulin resistance, obesity, and 
dyslipidemia, which in its turn in humans are strongly 
correlated with NAFLD [57-60]. It is increasingly docu-
mented that obesity without simultaneous inflammation 
does not result in peripheral insulin resistance, and simi-
larly, the steatosis will not lead to liver inflammation 
(NASH) and/or hepatic insulin resistance [57]. Wild type 
mice fed a high-fat diet, will normally develop obesity 
with simultaneous inflammation, insulin resistance and 
mild Type 2 diabetes. On the contrast, chimerical mice, 
lacking immune cells will become obese, but have a strik-
ing absence of insulin resistance. In addition, their livers 
will remain normal [61-63]. Among the proinflammatory 
molecules, TNF-α has been proposed to be the key link 
between obesity and insulin resistance. TNF-α is usually 
over- expressed in adipose tissues of obese animals and 
humans, and obese mice lacking TNF-α and/or its recep-
tor demonstrate protection against development of insu-
lin resistance[64,65].
To date, many lines of evidence seem to show that in 
humans chronic activation of proinflammatory pathways 
of insulin targetted cells can result in obesity/steatosis -
related insulin resistance. The influence of circulating 
and hepatic levels of proinflammatory cytokines TNF-α, 
IL-6, and C-reactive protein (CRP) in patients with 
NAFLD and their correlation with disease severity are 
well studied. Patients with NASH have generally signifi-
cantly higher levels of serum TNF-α and IL-6 than seen in 
patients with simple steatosis. NASH is, when compared 
to simple steatosis, associated with higher levels of solu-
ble TNF receptor 1 (sTNFR1) and soluble IL-6 receptor 
(sIL-6R) [66,67]. In addition, the expression is higher in 
those patients with more severe NASH. The findings that 
inflammation and insulin resistance often seem to occur 
in parallel and to reinforce each other via positive feed-
back mechanisms, suggesting that disruption of the inter-
face between inflammatory and metabolic pathways is 
central in the pathogenesis and progression (second hit) 
of NAFLD and also increase the risk of development of 
insulin resistance (Type 2 diabetes). Given the role of 
TNF-α in inducing both necroinflammation and IR, anti-
TNF agents have been considered for treatment of 
NASH. Reducing TNF-α signaling either by TNF-α 
knocking out mechanisms or by infusion of blocking anti-
bodies reduces insulin resistance in obese rodents [68]. 
Pentoxifylline, a TNF-α inhibitor, has also been used for 
the same purpose in patients with NASH. Two smaller 
studies in NASH patients report significant improve-
ments in AST and ALT and also significant improvement 
in insulin resistant after pentoxyfylline treatment [69,70], 
supporting the hypothesis that anti-inflammatory treat-
ments have favorable effects on NASH. However, TNF-α 
antibody treatment will not alter insulin sensitivity in 
humans [71]. Attempts in this study to over a period of 4 
weeks neutralize TNF-alpha with an engineered human 
anti-TNF-alpha antibody (CDP571) had no effect on 
insulin sensitivity in obese non-insulin-dependent diabe-
tes subjects with rheumatic diseases.
Fat can cause insulin resistance by prompting the activa-
tion of select serine kinases within a variety of insulin 
sensitive cells. The three serine kinases most strongly 
implicated in the pathogenesis of fat-induced insulin 
resistance are Jun N-terminal kinase (JNK), inhibitor of 
nuclear factor κB (NF-κB) kinase(IKK), and novel iso-
forms of protein kinase C (PKC) [72-74]. These enzymes 
will, alone or in combination, phosphorylate regulatory 
serine residues on the insulin receptor substrates IRS-1 
and IRS-2, leading to the downmodulation of normal 
insulin-stimulated tyrosine phosphorylation and interfer-
ing with physiologic insulin [57]. Among these, JNK and 
IKK are significantly effective proinflammatory signaling 
molecules. IKK and JNK cause inflammation by promot-
ing formation of the transcription factors AP-1 and NF-
κB, which activate transcription of a multitude of proin-
flammatory genes, cytokines, chemokines, and cell adhe-
sion molecules[75]. A causal connection between fat-
related activation of serine kinases and insulin resistance 
has been demonstrated in adipose tissue [76] and muscle 
[77] as well as liver [78-81]. Mice heterozygous for IKKβ 
are protected against the negative effects of a high-fat 
diet-associated obesity as well as development of insulin 
resistance [82]. Silencing of IKKβ will also prevent TNF-
alpha-induced impairments in the action of insulin on 
Akt phosphorylation and glucose uptake in primary 
human skeletal muscle myotubes from non-diabetic sub-
jects [83,84].
Also, fatty acids and high-fat feeding can, even in the 
absence of obesity or systemic insulin resistance, directly Liu et al. Lipids in Health and Disease 2010, 9:42
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induce inflammatory signaling through mammalian toll-
like receptors (TLRs) in the liver [85,86]. TLRs are cellu-
lar pattern-recognizing receptors (PRRs) that recognize 
the molecular patterns of pathogens, such as Gram-nega-
tive endotoxin. After engaging the pathogenic patterned 
ligands via a receptor-driven signaling cascade do they 
activate the transcription factor NF-κB, resulting in 
increased expression of proinflammatory cytokines, 
which in its turn trigger inflammation. Such rapid, innate 
cellular responses serve as the first line of host defense 
against infection by pathogens. Increasing evidence sug-
gests that TLRs also recognize host-derived ligands and 
interact with these endogenous ligands, generating tissue 
injury and cell death [87]. Thus TLRs will act as PRRs that 
paralle with the lipotoxicity and stress of endoplasmic 
reticulumt, use signaling mechanisms to solicit inflam-
mation and fat-induced insulin resistance (Fig 3). Such 
efforts should also reveal a wealth of potential targets for 
interventions and drug development that prevent 
NASH[88]. Probiotics, which reportedly suppress TLR-
related responses by altering the intestinal flora [89,90], 
reduce inflammation and improve the liver in animals 
and humans with fatty livers[91,92]. Similarly, dietary n-3 
polyunsaturated fatty acids, which are known inhibitors 
of TLR signaling[93], will have the capacity to suppress 
necro-inflammation and fibrosis in experimental fatty 
liver disease[94].
FoxO1 is a forkhead transcriptional factor that acts to 
mediate insulin action on target gene expression in 
peripheral cells [95-97]. More recent studies show that 
FoxO1 signaling through NF-kB plays a significant role in 
proinflammatory cytokine production and insulin resis-
tance (Fig 4). FoxO1 stimulate selectively macrophage 
production of IL-1β, but not IL-6, TNFα, and IFN-γ.
FoxO1 is known to mediate the inhibitory effect of insu-
lin on target gene expression. In the absence of insulin, 
FoxO1 acts in the nucleus as an enhancer of target gene 
expression, whereas in the presence of insulin, FoxO1, 
phosphorylated by Akt/PKB, will contribute to inhibition 
of target gene expression. The phosphorylation-depen-
dent protein trafficking mechanism is crucial for the reg-
ulation of FoxO1 transcriptional activity within cells [98-
100]. The IL-1β promoter contains sites for both FoxO1 
and NFkB target that are juxtapositioned within the pro-
moter-proximal region of the Il1b gene in mice, rats and 
humans, implying evolutionally conserved mechanisms 
or FoxO1 signaling through the NFkB pathway in regula-
tion of proinflammatory cytokines. Amelioration of insu-
lin resistance with blockage of IL-1β signaling via its 
receptor antagonist is associated with improving diabetes 
[101].
Conclusion
The molecular mechanisms underlying NAFLD and 
treatment options are this far poorly understood. Clearly, 
numerous factors are associated with increased activa-
tion of hepatic innate immune system, which is central to 
the development of fat-related insulin resistance and also 
plays an important role in fat-related liver damage 
(NASH). NASH is seemingly a much multifactorial con-
dition with some pathological end points such as 
increased hepatic oxidative stress, increased hepatic 
cytokine expression, direct "lipotoxicity" of excess circu-
Figure 4 Convergence of the FoxO1 and NFκB pathways in IL-1β 
gene expression: FoxO1 targets at the IRE DNA motif of the IL-1β 
promoter for trans-activation. This effect along with the activation 
of the NFκB pathways synergistically promotes macrophage produc-
tion of proinflammatory cytokine IL-1β. (Dongming Su et al. FoxO1 
Links Insulin Resistance to Proinflammatory Cytokine IL-1beta Produc-
tion in Macrophages. in Press).
Figure 3 Activation of inflammatory signaling pathways by 
fat(Hepatology. 2008;48:670-8).Liu et al. Lipids in Health and Disease 2010, 9:42
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lating NEFAs and insulin resistance. Especilly are the ser-
ine kinases key factors in the development of insulin 
resistance within hepatocytes and in other insulin sensi-
tive cells. Especially IKK and JNK, are important compo-
nents what is described as the two major 
proinflammatory pathways.
Future exploration of the signaling routes from fat to NF-
κB might provide information about hitherto unknown 
etiological factors behind chronic diseases in addition to 
those already known. It might also provide information 
about potentially new targets for drug development and 
treatment of these diseases.
Abbreviations
BMI: body mass index; NAFLD: nonalcoholic fatty liver disease; NASH: nonalco-
holic steatohepatitis; DNL: de novo lipogenesis; NEFA: non-esterified fatty acids; 
LDL: very low density lipoproteins; TG: triglycerides; CVD: cardiovascular dis-
ease; IFG: impaired fasting glucose; IGT: impaired glucose tolerance; SCD1: 
stearoyl-CoA desaturase-1; IR: insulin resistance; DM2: diabetes Mellitus Type 2; 
CRP: C-reactive protein; IL-6: interleukin-6; sTNFR1: TNF receptor 1; sIL-6R: solu-
ble IL-6 receptor; TLRs: Toll-like receptors; RAGE: receptor for advanced glyca-
tion end products; SIRS: systemic inflammatory response syndrome; JNK: Jun 
N-terminal kinase; NF-κB: nuclear factor κB; IKK: IκB kinase; PKC: protein kinase 
C.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
QL, SB and SQ conceived the study, its design and drafted the manuscript. All 
authors read and approved the final manuscript.
Author Details
1Deaprtment of Endocrinology, Tenth People's Hospital, Tongji University, 
Shanghai 200072, China, 2Departments of Hepatology and Surgery, University 
College London, 69 - 75 Chenies Mews, London, WC1E 6HX, UK and 3Beijing 
You An Hospital, Beijing 100006, China
References
1. Farrell GC, Chitturi S, Lau GK, Sollano JD, Asia-Pacific Working Party on 
NAFLD: Guidelines for the assessment and management of non-
alcoholic fatty liver disease in the Asia-Pacific region: executive 
summary.  J Gastroenterol Hepatol 2007, 22:775-7.
2. Adams LA, Angulo P: Recent concepts in non-alcoholic fattyliver 
disease.  Diabet Med 2005, 22:1129-1133.
3. Raman M, Allard J: Non alcoholic fatty liver disease: a clinical approach 
and review.  Can J Gastroenterol 2006, 20:345-9.
4. Fan JG: Impact of non-alcoholic fatty liver disease on accelerated 
metabolic complications.  J Dig Dis 2008, 9:63-7.
5. Boppidi H, Daram SR: Nonalcoholic fatty liver disease: hepatic 
manifestation of obesity and the metabolic syndrome.  Postgrad Med 
2008, 120:E01-7.
6. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, 
Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke 
C, DeFronzo R, Bannayan GA, Schenker S, Cusi K: A placebo-controlled 
trial of pioglitazone in subjects with nonalcoholic steatohepatitis.  N 
Engl J Med 2006, 355:2297-307.
7. Chávez-Tapia NN, Uribe M, Ponciano-Rodríguez G, Medina-Santillán R, 
Méndez-Sánchez N: New insights into the pathophysiology of 
nonalcoholic fatty liver disease.  Ann Hepatol 2009, 8:S9-S17.
8. Abrams GA, Kunde SS, Lazenby AJ, Clements RH: Portal fibrosis and 
hepatic steatosis in morbidly obese subjects: a spectrum of 
nonalcoholic fatty liver disease.  Hepatology 2004, 40:475-83.
9. Chavez-Tapia NC, Tiribelli C: Are non-invasive tests accurate enough to 
predict hepatic fibrosis in non-alcoholic fatty liver disease (NAFLD)?  
Gut 2008, 57:1351-3.
10. Brunt EM: Nonalcoholic steatohepatitis: pathologic features and 
differential diagnosis.  Semin Diagn Pathol 2005, 22:330-338.
11. Yeh MM, Brunt EM: Pathology of nonalcoholic fatty liver disease.  Am J 
Clin Pathol 2007, 128:837-847.
12. Tiniakos DG: Nonalcoholic fatty liverdisease/nonalcoholic 
steatohepatitis: Histological diagnostic criteria and scoring systems.  
European Journal of Gastroenterology & Hepatology 2009, 00:.
13. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ: 
Sources of fatty acids stored in liver and secreted via lipoproteins in 
patients with nonalcoholic fatty liver disease.  J Clin Invest 2005, 
115:1343-1351.
14. Abdul-Ghani MA, Tripathy D, DeFronzo RA: Contributions of beta-cell 
dysfunction and insulin resistance to the pathogenesis of impaired 
glucose tolerance and impaired fasting glucose.  Diabetes Care 2006, 
29:1130-9.
15. Hanefeld M, Koehler C, Fuecker K, Henkel E, Schaper F, Temelkova-
Kurktschiev T, Impaired Glucose Tolerance for Atherosclerosis and 
Diabetes study: Insulin secretion and insulin sensitivity pattern is 
different in isolated impaired glucose tolerance and impaired fasting 
glucose: the risk factor in Impaired Glucose Tolerance for 
Atherosclerosis and Diabetes study.  Diabetes Care 2003, 26:868-74.
16. Postic C, Girard J: The role of the lipogenic pathway in the development 
of hepatic steatosis.  Diabetes & Metabolism 2008, 34:643-648.
17. Koch L, Wunderlich FT, Seibler J, Könner AC, Hampel B, Irlenbusch Brabant 
G, Kahn CR, Schwenk F, Brüning JC: Central insulin action regulates 
peripheral glucose and fat metabolism in mice.  J Clin Invest 2008, 
118:2132-47.
18. Blüher M, Michael MD, Peroni OD, Ueki K, Carter N, Kahn BB, Kahn CR: 
Adipose tissue selective insulin receptor knockout protects against 
obesity and obesity-related glucose intolerance.  Dev Cell 2002, 3:25-38.
19. Reddy JK, Rao MS: Lipid Metabolism and Liver Inflammation. II. Fatty 
liver disease and fatty acid oxidation.  Am J Physiol Gastrointest Liver 
Physiol 2006, 290:G852-G858.
20. den Boer M, Voshol PJ, Kuipers F, Havekes LM, Romijn JA: Hepatic 
steatosis: a mediator of the metabolic syndrome. Lessons from animal 
models.  Arterioscler Thromb Vasc Biol 2004, 24:644-9.
21. Schonfeld G, Yue P, Lin X, Chen Z: Fatty liver and insulin resistance: not 
always linked.  Trans Am Clin Climatol Assoc 2008, 119:217-23.
22. Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, Befroy D, Romanelli AJ, Shulman 
GI: Mechanism of hepatic insulin resistance in non-alcoholic fatty liver 
disease.  Biol Chem 2004, 279:32345-53.
23. Saito T, Misawa K, Kawata S1: Fatty liver and non-alcoholic 
steatohepatitis.  Intern Med 2007, 46:101-3.
24. Duckworth WC, Bennett RG, Hamel FG: Insulin degradation: progress 
and potential.  Endocr Rev 1998, 19:608-624.
25. Meier JJ, Veldhuis JD, Butler PC: Pulsatile insulin secretion dictates 
systemic insulin delivery by regulating hepatic insulin extraction in 
humans.  Diabetes 2005, 54:1649-56.
26. Field JB: Extraction of insulin by liver.  Annu Rev Med 1973, 24:309-314.
27. Polonsky K, Jaspan J, Emmanouel D, et al.: Differences in the hepatic and 
renal extraction of insulin and glucagon in the dog: evidence for 
saturability of insulin metabolism.  Acta Endocrinol 1983, 102:420-427.
28. Kaden M, Harding P, Field JB: Effect of intraduodenal glucose 
administration on hepatic extraction of insulin in the anesthetized 
dog.  J Clin Invest 1973, 52:2016-2028.
29. Meistas MT, Rendell M, Margolis S, Kowarski AA: Estimation of the 
secretion rate of insulin from the urinary excretion rate of C-peptide: 
study in obese and diabetic subjects.  Diabetes 1982, 31:449-453.
30. Eaton RP, Allen RC, Schade DS: Hepatic removal of insulin in normal 
man:dose response to endogenous insulin secretion.  J Clin Endocrinol 
Metab 1983, 56:1294-1300.
31. Waldhäusl W, Bratusch-Marrain P, Gasic S, Korn A, Nowotny P: 
Insulinproduction rate following glucose ingestion estimated by 
splanchnic C-peptide output in normal man.  Diabetologia 1979, 
17:221-227.
32. Polonsky KS, Rubenstein AH: C-peptide as a measure of the secretion 
and hepatic extraction of insulin: pitfalls and limitations.  Diabetes 1984, 
33:486-494.
Received: 23 February 2010 Accepted: 28 April 2010 
Published: 28 April 2010
This article is available from: http://www.lipidworld.com/content/9/1/42 © 2010 Liu et al; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Lipids in Health and Disease 2010, 9:42Liu et al. Lipids in Health and Disease 2010, 9:42
http://www.lipidworld.com/content/9/1/42
Page 8 of 9
33. Kotronen A, Vehkavaara S, Seppälä-Lindroos A, Bergholm R, Yki-Järvinen 
H: Effect of liver fat on insulin clearance.  Am J Physiol Endocrinol Metab 
2007, 293:E1709-15.
34. Kotronen A, Juurinen L, Tiikkainen M, Vehkavaara S, Yki-Järvinen H: 
Increased liver fat, impaired insulin clearance, and hepatic and adipose 
tissue insulin resistance in type 2 diabetes.  Gastroenterology 2008, 
135:122-30.
35. Chalasani N, Wilson L, Kleiner DE, Cummings OW, Brunt EM, Unalp A, 
NASH Clinical Research Network: Relationship of steatosis grade and 
zonal location to histological features of steatohepatitis in adult 
patients with non-alcoholic fatty liver disease.  J Hepatol 2008, 
48:829-834.
36. Postic C, Girard J: Contribution of de novo fatty acid synthesis to hepatic 
steatosis and insulin resistance: lessons from genetically engineered 
mice.  J Clin Invest 2008, 118:829-38.
37. Choi SS, Diehl AM: Hepatic triglyceride synthesis and nonalcoholic fatty 
liver disease.  Curr Opin Lipidol 2008, 19:295-300.
38. Yamaguchi K, Yang L, McCall S, Huang J, Yu XX, Pandey SK, Bhanot S, 
Monia BP, Li YX, Diehl AM: Inhibiting triglyceride synthesis improves 
hepatic steatosis but exacerbates liver damage and fibrosis in obese 
mice with nonalcoholic steatohepatitis.  Hepatology 2007, 45:1366-74.
39. Li ZZ, Berk M, McIntyre TM, Feldstein AE: Hepatic lipid partitioning and 
liver damage in nonalcoholic fatty liver disease: role of stearoyl-CoA 
desaturase.  J Biol Chem 2009, 284:5637-44.
40. Paton CM, Ntambi JM: Biochemical and physiological function of 
stearoyl-CoA desaturase.  Am J Physiol Endocrinol Metab 2009, 
297:E28-37.
41. Kotronen A, Seppänen-Laakso T, Westerbacka J, Kiviluoto T, Arola J, 
Ruskeepää AL, Oresic M, Yki-Järvinen H: Hepatic stearoyl-coa desaturase 
(scd)-1 activity and diacylglycerol but not ceramide concentrations are 
increased in the nonalcoholic human fatty liver.  Diabetes 2009, 
58:203-8.
42. Shimano H, Yahagi N, Amemiya-Kudo M, Hasty AH, Osuga J, Tamura Y, 
Shionoiri F, Iizuka Y, Ohashi K, Harada K, Gotoda T, Ishibashi S, Yamada N: 
Sterol regulatory element-binding protein-1 as a key transcription 
factor for nutritional induction of lipogenic enzyme genes.  J Biol Chem 
1999, 274:35832-9.
43. Brown JM, Chung S, Sawyer JK, Degirolamo C, Alger HM, Nguyen T, Zhu X, 
Duong MN, Brown AL, Lord C, Shah R, Davis MA, Kelley K, Wilson MD, 
Madenspacher J, Fessler MB, Parks JS, Rudel LL: Combined therapy of 
dietary fish oil and stearoyl-CoA desaturase 1 inhibition prevents the 
metabolic syndrome and atherosclerosis.  Arterioscler Thromb Vasc Biol 
2010, 30:24-30.
44. Brown JM, Chung S, Sawyer JK, Degirolamo C, Alger HM, Nguyen T, Zhu X, 
Duong MN, Wibley AL, Shah R, Davis MA, Kelley K, Wilson MD, Kent C, 
Parks JS, Rudel LL: Inhibition of stearoyl-coenzyme A desaturase 1 
dissociates insulin resistance and obesity from atherosclerosis.  
Circulation 2008, 118:1467-75.
45. Flowers MT, Ntambi JM: Role of stearoyl-coenzyme A desaturase in 
regulating lipid metabolism.  Curr Opin Lipidol 2008, 19:248-56.
46. Chalasani N, Wilson L, Kleiner DE, Cummings OW, Brunt EM, Unalp A, 
NASH Clinical Research Network: Relationship of steatosis grade and 
zonal location to histological features of steatohepatitis in adult 
patients with non-alcoholic fatty liver disease.  J Hepatol 2008, 
48:829-834.
47. Vuppalanchi R, Cummings OW, Saxena R, Ulbright TM, Martis N, Jones DR, 
Bansal N, Chalasani N: Hepatic steatosis relationship among 
histological, radiological and biochemical assessments.  J Clin 
Gastroenterol 2007, 41:206-210.
48. Rinella ME, McCarthy R, Thakrar K, Finn JP, Rao SM, Koffron AJ, Abecassis 
M, Blei AT: Dual-echo, chemical shift gradient-echo magnetic 
resonance imaging to quantify hepatic steatosis: Implications for living 
liver donation.  Liver Transplantation 2003, 9:851-856.
49. Zhang B, Menzin J, Friedman M, Korn JR, Burge RT: Predicted coronary 
risk for adults with coronary heart disease and low HDL-C: an analysis 
from the US National Health and Nutrition Examination Survey.  Curr 
Med Res Opin 2008, 24:2711-7.
50. Adams LA, Waters OR, Knuiman MW, Elliott RR, Olynyk JK: NAFLD as a risk 
factor for the development of diabetes and the metabolic syndrome: 
an eleven-year follow-up study.  Am J Gastroenterol 2009, 104:861-7.
51. Mills SJ, Harrison SA: Comparison of the natural history of alcoholic and 
nonalcoholic fatty liver disease.  Curr Gastroenterol Rep 2005, 7:32-6.
52. Liou I, Kowdley KV: Natural history of nonalcoholic steatohepatitis.  J 
Clin Gastroenterol 2006, 40(Suppl 1):S11-6.
53. Farrell GC, Larter CZ: Nonalcoholic fatty liver disease: from steatosis to 
cirrhosis.  Hepatology 2006, 43:S99-S112.
54. Rubinstein E, Lavine JE, Schwimmer JB: Hepatic, cardiovascular, and 
endocrine outcomes of the histological subphenotypes of 
nonalcoholic fatty liver disease.  Semin Liver Dis 2008, 28:380-5.
55. Yatsuji S, Hashimoto E, Tobari M, Taniai M, Tokushige K, Shiratori K: Clinical 
features and outcomes of cirrhosis due to non-alcoholic 
steatohepatitis compared with cirrhosis caused by chronic hepatitis C.  
J Gastroenterol Hepatol 2009, 24:248-54.
56. Dowman JK, Tomlinson JW, Newsome PN: Pathogenesis of non-
alcoholic fatty liver disease.  QJM 2010, 103:71-83.
57. Maher JJ, Leon P, Ryan JC: Beyond insulin resistance: Innate immunity in 
nonalcoholic steatohepatitis.  Hepatology 2008, 48:670-8.
58. Diehl AM: Nonalcoholic Steatosis and Steatohepatitis IV. Nonalcoholic 
fatty liver disease abnormalities in macrophage function and 
cytokines.  Am J Physiol Gastrointest Liver Physiol 2002, 282:G1-G5.
59. Li Z, Diehl AM: Innate immunity in the liver.  Curr Opin Gastroenterol 2003, 
19:565-71.
60. Choi S, Diehl AM: Role of inflammation in nonalcoholic steatohepatitis.  
Curr Opin Gastroenterol 2005, 21:702-7.
61. Perseghin G, Petersen K, Shulman GI: Cellular mechanism of insulin 
resistance: potential links with inflammation.  Int J Obes Relat Metab 
Disord 2003, 27(Suppl 3):S6-S11.
62. Lee JY, Hwang DH: The modulation of inflammatory gene expression 
by lipids: mediation through Toll-like receptors.  Mol Cell 2006, 
21:174-185.
63. Kim JK, Kim YJ, Fillmore JJ, Chen Y, Moore I, Lee J, Yuan M, Li ZW, Karin M, 
Perret P, Shoelson SE, Shulman GI: Prevention of fat-induced insulin 
resistance by salicylate.  J Clin Invest 2001, 108:437-446.
64. Borst SE, Lee Y, Conover CF, Shek EW, Bagby GJ: Neutralization of tumor 
necrosis factor-alpha reverses insulin resistance in skeletal muscle but 
not adipose tissue.  Am J Physiol Endocrinol Metab 2004, 287:E934-8.
65. Lorenzo M, Fernández-Veledo S, Vila-Bedmar R, Garcia-Guerra L, De Alvaro 
C, Nieto-Vazquez I: Insulin resistance induced by tumor necrosis factor-
alpha in myocytes and brown adipocytes.  J Anim Sci 2008, 86(14 
Suppl):E94-104.
66. Abiru S, Migita K, Maeda Y, Daikoku M, Ito M, Ohata K, Nagaoka S, 
Matsumoto T, Takii Y, Kusumoto K, Nakamura M, Komori A, Yano K, 
Yatsuhashi H, Eguchi K, Ishibashi H: Serum cytokine and soluble cytokine 
receptor levels in patients with non-alcoholic steatohepatitis.  Liver Int 
2006, 26:39-45.
67. Bahcecioglu IH, Yalniz M, Ataseven H, Ilhan N, Ozercan IH, Seckin D, Sahin 
K: Levels of serum hyaluronic acid, TNF-alpha and IL-8 in patients with 
nonalcoholic steatohepatitis.  Hepatogastroenterology 2005, 52:1549-53.
68. Grabig A, Paclik D, Guzy C, Dankof A, Baumgart DC, Erckenbrecht J, 
Raupach B, Sonnenborn U, Eckert J, Schumann RR, Wiedenmann B, 
Dignass AU, Sturm A: Escherichia coli strain Nissle 1917 ameliorates 
experimental colitis via toll-like receptor 2- and toll-like receptor 4-
dependent pathways.  Infect Immun 2006, 74:4075-4082.
69. Satapathy SK, Garg S, Chauhan R, Sakhuja P, Malhotra V, Sharma BC, Sarin 
SK: Beneficial effects of tumor necrosis factor-alpha inhibition by 
pentoxifylline on clinical, biochemical, and metabolic parameters of 
patients with nonalcoholic steatohepatitis.  Am J Gastroenterol 2004, 
99:1946-52.
70. Adams LA, Zein CO, Angulo P, Lindor KD: A pilot trial of pentoxifylline in 
nonalcoholic steatohepatitis.  Am J Gastroenterol 2004, 99:2365-8.
71. Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R: Effects of an engineered 
human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and 
glycemic control in patients with NIDDM.  Diabetes 1996, 45:881-5.
72. Hotamisligil GS: Role of endoplasmic reticulum stress and c-Jun NH2-
terminal kinase pathways in inflammation and origin of obesity and 
diabetes.  Diabetes 2005, 54(Suppl 2):S73-S78.
73. Perseghin G, Petersen K, Shulman GI: Cellular mechanism of insulin 
resistance: potential links with inflammation.  Int J Obes Relat Metab 
Disord 2003, 27(Suppl 3):S6-S11.
74. Shoelson SE, Lee J, Goldfine AB: Inflammation and insulin resistance.  J 
Clin Invest 2006, 116:1793-1801.
75. Malhi H, Bronk SF, Werneburg NW, Gores GJ: Free fatty acids induce JNK-
dependent hepatocyte lipoapoptosis.  J Biol Chem 2006, 
281:12093-12101.Liu et al. Lipids in Health and Disease 2010, 9:42
http://www.lipidworld.com/content/9/1/42
Page 9 of 9
76. Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD, Gores GJ: 
Hepatocyte apoptosis and fas expression are prominent features of 
human nonalcoholic steatohepatitis.  Gastroenterology 2003, 
125:437-443.
77. Schattenberg JM, Singh R, Wang Y, Lefkowitch JH, Rigoli RM, Scherer PE, 
Czaja MJ: JNK1 but not JNK2 promotes the development of 
steatohepatitis in mice.  Hepatology 2006, 43:163-172.
78. Gao Z, Zhang X, Zuberi A, Hwang D, Quon MJ, Lefevre M, Ye J: Inhibition 
of insulin sensitivity by free fatty acids requires activation of multiple 
serine kinases in 3T3-L1 adipocytes.  Mol Endocrinol 2004, 18:2024-2034.
79. Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, Befroy D, Romanelli AJ, Shulman 
GI: Mechanism of hepatic insulin resistance in non-alcoholic fatty liver 
disease.  J Biol Chem 2004, 279:32345-32353.
80. Samuel VT, Liu ZX, Wang A, Beddow SA, Geisler JG, Kahn M, Zhang XM, 
Monia BP, Bhanot S, Shulman GI: Inhibition of protein kinase Cepsilon 
prevents hepatic insulin resistance in nonalcoholic fatty liver disease.  J 
Clin Invest 2007, 117:739-745.
81. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE: Local 
and systemic insulin resistance resulting from hepatic activation of 
IKKbeta and NF-kappaB.  Nat Med 2005, 11:183-190.
82. Carter-Kent C, Zein NN, Feldstein AE: Cytokines in the pathogenesis of 
fatty liver and disease progression to steatohepatitis: implications for 
treatment.  Am J Gastroenterol 2008, 103:1036-42.
83. Austin RL, Rune A, Bouzakri K, Zierath JR, Krook A: siRNA-mediated 
reduction of inhibitor of nuclear factor-kappaB kinase prevents tumor 
necrosis factor-alpha-induced insulin resistance in human skeletal 
muscle.  Diabetes 2008, 57:2066-73.
84. Bouzakri K, Zierath JR: MAP4K4 gene silencing in human skeletal muscle 
prevents tumor necrosis factor-alpha-induced insulin resistance.  J Biol 
Chem 2007, 282:7783-9.
85. Song MJ, Kim KH, Yoon JM, Kim JB: Activation of Toll-like receptor 4 is 
associated with insulin resistance in adipocytes.  Biochem Biophys Res 
Commun 2006, 4;346(3):739-45.
86. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS: TLR4 links innate 
immunity and fatty acid-induced insulin resistance.  J Clin 2006, 
116(11):3015-25.
87. Medzhitov R, Janeway C Jr: Innate immunity.  N Engl J Med 2000, 
343:338-344.
88. Tsukumo DM, Carvalho-Filho MA, Carvalheira JB, Prada PO, Hirabara SM, 
Schenka AA, Araújo EP, Vassallo J, Curi R, Velloso LA, Saad MJ: Loss-of-
function mutation in Toll-like receptor 4 prevents diet-induced obesity 
and insulin resistance.  Diabetes 2007, 56(8):1986-98.
89. Grabig A, Paclik D, Guzy C, Dankof A, Baumgart DC, Erckenbrecht J, 
Raupach B, Sonnenborn U, Eckert J, Schumann RR, Wiedenmann B, 
Dignass AU, Sturm A: Escherichia coli strain Nissle 1917 ameliorates 
experimental colitis via toll-like receptor 2- and toll-like receptor 4-
dependent pathways.  Infect Immun 2006, 74:4075-4082.
90. Rachmilewitz D, Katakura K, Karmeli F, Hayashi T, Reinus C, Rudensky B, 
Akira S, Takeda K, Lee J, Takabayashi K, Raz E: Toll-like receptor 9 signaling 
mediates the anti-inflammatory effects of probiotics in murine 
experimental colitis.  Gastroenterology 2004, 126:520-528.
91. Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, Desimone C, Song XY, 
Diehl AM: Probiotics and antibodies to TNF inhibit inflammatory 
activity and improve nonalcoholic fatty liver disease.  Hepatology 2003, 
37:343-350.
92. Loguercio C, Federico A, Tuccillo C, Terracciano F, D'Auria MV, De Simone 
C, Del Vecchio Blanco C: Beneficial effects of a probiotic VSL#3 on 
parameters of liver dysfunction in chronic liver diseases.  J Clin 
Gastroenterol 2005, 39:540-543.
93. Lee JY, Zhao L, Youn HS, Weatherill AR, Tapping R, Feng L, Lee WH, 
Fitzgerald KA, Hwang DH: Saturated fatty acid activates but 
polyunsaturated fatty acid inhibits Tolllike receptor 2 dimerized with 
Toll-like receptor 6 or 1.  J Biol Chem 2004, 279:16971-16979.
94. Svegliati-Baroni G, Candelaresi C, Saccomanno S, Ferretti G, Bachetti T, 
Marzioni M, De Minicis S, Nobili L, Salzano R, Omenetti A, Pacetti D, 
Sigmund S, Benedetti A, Casini A: A model of insulin resistance and 
nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-
activated receptor-alpha and n-3 polyunsaturated fatty acid treatment 
on liver injury.  Am J Pathol 2006, 169:846-860.
95. Accili D, Arden KC: FoxOs at the crossroads of cellular metabolism, 
differentiation, and transformation.  Cell 2004, 117:421-426.
96. Barthel A, Schmoll D, Unterman TG: FoxO proteins in insulin action and 
metabolism.  Trends Endocrinol Metab 2005, 16:183-189.
97. Kamagate A, Dong HH: FoxO1 integrates insulin signaling to VLDL 
production.  Cell Cycle 2008, 7:3162-3170.
98. Altomonte J, Cong L, Harbaran S, Richter A, Xu J, Meseck M, Dong HH: 
Foxo1 Mediates Insulin Action on ApoC-III and Triglyceride 
Metabolism.  J Clin Invest 2004, 114:1493-1503.
99. Qu S, Altomonte J, Perdomo G, He J, Fan Y, Kamagate A, Meseck M, Dong 
HH: Aberrant Forkhead box O1 function is associated with impaired 
hepatic metabolism.  Endocrinology 2006, 147:5641-5652.
100. Kamagate A, Qu S, Perdomo G, Su D, Kim DH, Slusher S, Meseck M, Dong 
HH: FoxO1 mediates insulin-dependent regulation of hepatic VLDL 
production in mice.  J Clin Invest 2008, 118:2347-2364.
101. Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, Seifert B, Mandrup-
Poulsen T, Donath MY: Interleukin-1-receptor antagonist in type 2 
diabetes mellitus.  N Engl J Med 2007, 356:1517-1526.
doi: 10.1186/1476-511X-9-42
Cite this article as: Liu et al., The role of hepatic fat accumulation in patho-
genesis of non-alcoholic fatty liver disease (NAFLD) Lipids in Health and Dis-
ease 2010, 9:42